(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 April 2013 (18.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/056108 A2

(51) **International Patent Classification**:
*A61K 9/00* (2006.01)

(21) **International Application Number**:
PCT/US2012/060044

(22) **International Filing Date**:
12 October 2012 (12.10.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/547,620 14 October 2011 (14.10.2011) US
61/606,207 2 March 2012 (02.03.2012) US

(71) **Applicant** *(for all designated States except US)*: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **FRY, David Shank** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **LINDEMANN, Christopher M.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **PREIGH, Michael** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BLOOM, Corey Jay** [US/US]; c/o Bend Research, 64550 Research Road, Bend, Oregon 97701 (US). **CRAIG, Christopher Donovan** [US/US]; c/o Bend Research, 64550 Research Road, Bend, Oregon 97701 (US). **DUBOSE, Devon Brevard** [US/US]; c/o Bend Research, 64550 Research Road, Bend, Oregon 97701 (US). **GAUTSCHI, Jeff** [US/US]; c/o Agere Pharmaceuticals, 62925 NE 18th Street, Bend, Oregon 97701 (US). **SMITHEY, Dan** [US/US]; c/o Agere Pharmaceuticals, 62925 NE 18th Street, Bend, Oregon 97701 (US).

(74) **Agents**: **HARRIS, Robert J.** et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, St. Paul, Minnesota 5111-1098 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*[Continued on next page]*

(54) **Title**: SOLID DISPERSION





FIGURE 1

(57) **Abstract**: A solid dispersion of *N4*-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-*N6*-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of *N*4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.

WO 2013/056108 A2

**Published**:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*